When administered under medical supervision at standard low doses, ketamine therapy carries a low risk of addiction. However, ketamine is a Schedule III controlled substance with recognized abuse potential, and recreational misuse at higher doses and frequencies can lead to psychological dependence and tolerance. The structured clinical setting -- with controlled dosing, medical monitoring, and treatment intervals of weeks between sessions -- is fundamentally different from patterns of recreational use and substantially reduces addiction risk.
Understanding the Distinction
The critical distinction is between supervised clinical use and unsupervised recreational use. Clinical ketamine therapy involves low sub-anesthetic doses (typically 0.5 mg/kg IV) administered in a controlled medical setting at intervals of weeks to months. Recreational ketamine abuse involves self-administered doses that are often much higher, used much more frequently, and taken specifically to produce dissociative or euphoric effects.
Published studies tracking patients receiving clinical ketamine treatment for depression have not reported significant rates of addiction or compulsive drug-seeking behavior. A 2018 consensus statement from the American Psychiatric Association noted that while ketamine has abuse potential, the clinical evidence at that time did not indicate high addiction rates when used in supervised therapeutic protocols.
Risk Factors and Safeguards
Certain patients may face higher risk, including those with a personal history of substance use disorders. Most ketamine clinics conduct thorough screening that includes substance use history as part of the patient selection process. A history of ketamine abuse or active substance use disorder may be a relative or absolute contraindication depending on the clinical context.
Safeguards built into clinical protocols help minimize addiction risk:
- Treatments are administered in-clinic, not dispensed for home use (with some exceptions for supervised sublingual protocols)
- Dosing follows standardized weight-based guidelines
- Treatment frequency is limited to what is clinically necessary
- Patients are monitored for signs of misuse or dose escalation
It is worth noting that tolerance -- needing higher doses for the same effect -- has been reported with frequent ketamine use, but this is primarily documented in recreational users. Clinical patients treated at standard intervals rarely develop clinically significant tolerance.
For comprehensive information on ketamine safety, see the Complete Guide to Low-Dose Ketamine Therapy.
References
- PubMed: APA Council of Research Task Force on Novel Biomarkers and Treatments: Ketamine and Related Compounds — APA consensus statement on ketamine use and abuse potential
- DEA: Ketamine Drug Fact Sheet — Drug Enforcement Administration scheduling and abuse information
- PubMed: Abuse Potential of Ketamine: A Review — Systematic review of ketamine dependence and abuse liability
Share